NCT06308510Recruiting
Detection of Aneuploidy in Cell Free DNA to Improve the Sensitivity of Diagnostic Peritoneal Lavage in Gastric Cancer
Source: ClinicalTrials.gov · Last updated 14 Sept 2026
Brief summary (registry, in English)
Aneuploidy may be used as a more sensitive diagnostic tool to detect peritoneal metastasis compared to conventional cytology and imaging techniques. Our aim is to establish whether aneuploidy as detected in cfDNA (as a measure for ctDNA) in PLF of patients with GC may hold value as an additional staging and tumor evaluation method in GC patients.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 63 (estimated)
- First submitted
- 7 Mar 2024
- Start date
- 17 Dec 2024
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Erasmus Medical Center
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT06308510
What you commit to
- Study type: Observational
- Planned participants: 63
- From 17 Dec 2024 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- \- Language difficulty, dementia or altered mental status prohibiting the under-standing and giving of informed consent.
- non-cancer controls:
- Active inflammation or infection;
- Subjects with previous malignancies are excluded unless a complete remission was achieved at least 5 years prior to study entry (exceptions include but are not limited to, non-melanoma skin cancers; in situ bladder cancer, or in situ co-lon cancers; in situ cervical cancers/dysplasia; or breast carcinoma in situ).
Who the study is looking for
- Age ≥18 years old;
- Written informed consent according to the ICH-GCP and national/local regula-tions.
- Operable patients who will undergo a planned diagnostic laparoscopy for a benign indication bariatric or gallbladder disease);
- Age ≥18 years old;
- Written informed consent according to the ICH-GCP and national/local regulations.
Criteria the registry did not label
- Gastric cancer patients:
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Erasmus MC Coordinator of this site? Confirm its status | Rotterdam | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.